Nintedanib Side Effects
Applies to nintedanib: oral capsule.
Serious side effects of nintedanib
Along with its needed effects, nintedanib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking nintedanib:
More common side effects
Less common side effects
- black, tarry stools
- blood in the urine
- blurred vision
- bruising or purple areas on the skin
- chest pain or discomfort
- coughing up blood
- decreased alertness
- dizziness
- headache
- irregular heartbeat
- joint pain or swelling
- nervousness
- nosebleeds
- pain in the chest, groin, or legs, especially calves of the legs
- pain or discomfort in the arms, jaw, back, or neck
- pounding in the ears
- severe headaches of sudden onset
- slow or fast heartbeat
- stomach swelling
- sudden loss of coordination
- sudden onset of slurred speech
- sudden vision changes
- sweating
- trouble breathing
Incidence not known
- bleeding gums
- bloating
- chills
- cloudy urine
- constipation
- difficult or painful urination
- fast heartbeat
- fever
- indigestion
- pains in the stomach, side, or abdomen, possibly radiating to the back
- pinpoint red spots on the skin
- sudden increase or decrease in amount of urine
- swelling of face, feet, or lower legs
- unusual bleeding or bruising
- weight gain
Other side effects of nintedanib
Some side effects of nintedanib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common side effects
Less common side effects
- depression
- dry skin and hair
- feeling cold
- hair loss
- hoarseness or husky voice
- muscle cramps and stiffness
- slow heartbeat
- unusual tiredness or weakness
For healthcare professionals
Applies to nintedanib: oral capsule.
General adverse events
The most common adverse reactions (incidence greater than 5%) included diarrhea, nausea, abdominal pain, vomiting, liver enzyme elevation, decreased appetite, headache, decreased weight, and hypertension.[Ref]
Cardiovascular
- Common (1% to 10%): Hypertension, arterial thromboembolic events, venous thromboembolism
- Uncommon (0.1% to 1%): Myocardial infarction
- Frequency not reported: Aneurysms and artery dissections
Dermatologic
- Very common (10% or more): Skin ulcer (18%)
- Common (1% to 10%): Alopecia, rash
- Uncommon (0.1% to 1%): Pruritus
Endocrine
- Common (1% to 10%): Hypothyroidism
Gastrointestinal
- Very common (10% or more): Diarrhea (up to 76%), nausea (up to 32%), vomiting (up to 25%), abdominal/esophageal pain (up to 18%), mucositis
- Common (1% to 10%): Constipation
- Uncommon (0.1% to 1%): Pancreatitis, colitis
- Postmarketing reports: Gastrointestinal perforation
Hematologic
- Very common (10% or more): Neutropenia (up to 13.8%), decreased hemoglobin (up to 11.2%)
- Common (1% to 10%): Bleeding, febrile neutropenia
- Uncommon (0.1% to 1%): Thrombocytopenia
- Postmarketing reports: Bleeding events
Hepatic
- Very common (10% or more): Liver enzyme elevation (up to 14%), increased ALT
- Common (1% to 10%): Hyperbilirubinemia, increased ALT, increased GGT, increased blood alkaline phosphatase
- Uncommon (0.1% to 1%): Drug induced liver injury
Metabolic
- Very common (10% or more): Electrolyte imbalance
- Uncommon (0.1% to 1%): Dehydration
Musculoskeletal
- Common (1% to 10%): Back pain
Nervous system
- Very common (10% or more): Peripheral neuropathy
- Common (1% to 10%): Headache, dizziness
Other
- Very common (10% or more): Decreased weight (up to 12%), fatigue (up to 11%), Decreased appetite (up to 11%)
- Common (1% to 10%): Pyrexia, sepsis, abscesses
Renal
- Uncommon (0.1% to 1%): Renal failure
- Postmarketing reports: Proteinuria
Respiratory
- Very common (10% or more): Cough (up to 15.2%)
References
1. (2022) "Product Information. Ofev (nintedanib)." Boehringer Ingelheim
2. (2024) "Product Information. Ofev (nintedanib)." Boehringer Ingelheim Pty Ltd
3. (2023) "Product Information. Ofev (nintedanib)." Boehringer Ingelheim Ltd
4. (2023) "Product Information. Vargatef (nintedanib)." Boehringer Ingelheim Ltd
Frequently asked questions
More about nintedanib
- Check interactions
- Compare alternatives
- Reviews (36)
- Dosage information
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Nintedanib side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.